Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)

In vitro diagnostics (IVDs) play a critical role in diagnosis, proper treatment decisions, and monitoring patient outcomes. The European Union’s new In Vitro Diagnostic Regulation (IVDR) introduces significant changes for IVD manufacturers, necessitating a comprehensive understanding of the regulatory approval requirements to market a product in Europe. The requirements now include clinical and scientific evidence to support the validity of the IVD, as has been standard for reviews of therapeutic products for many years. Manufacturers should familiarize themselves with the key regulatory changes and adhere to the transition timelines specified by the IVDR to ensure compliance and continued access to the European market for their IVDs.

Open PDF

Return to Insights Center

Related Insights


New FDA draft guidance: Implications for simplifying interchangeability for biosimilars in the US

Jul 16, 2024


Relyvrio Approval: Lessons Learned

Oct 31, 2022


RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry

Jun 16, 2022


8 things you need to know about eCTDs in China

Jul 1, 2022


Preparing for the New Era of Hybrid Regulatory Inspections

Jul 11, 2022


EU Orphan Drug Designation – overcoming regulatory challenges

Jul 20, 2022


Cell & Gene Therapies: A Regulatory Update

Jul 22, 2022


U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?

Aug 17, 2022


Q&A Project Optimus: What you need to know

Oct 11, 2022


Five strategies for meeting the requirements of Project Optimus and improving the chances of approval

Nov 10, 2022


New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

May 10, 2022


Are you using real-world evidence?

Feb 1, 2023